Detalhe da pesquisa
1.
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
N Engl J Med;
354(24): 2542-51, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16775235
2.
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
J Clin Oncol;
23(30): 7583-93, 2005 Oct 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16234522
3.
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Clin Cancer Res;
9(13): 4674-81, 2003 Oct 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14581336
4.
Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.
Best Pract Res Clin Haematol;
15(4): 757-69, 2002 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12617875
5.
Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms.
Leuk Res;
28(11): 1153-7, 2004 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15380338
6.
[Therapy of Philadelphia chromosome positive acute lymphatic leukemia (Ph+ ALL) with an inhibitor of abl-tyrosine kinase (Glivec)]. / Therapie der Philadelphia-Chromosom-positiven akuten lymphatischen Leukämie (Ph+ ALL) mit einem Inhibitor der abl-Tyrosinkinase (Glivec).
Med Klin (Munich);
97 Suppl 1: 16-21, 2002 Jan 15.
Artigo
em Alemão
| MEDLINE
| ID: mdl-11831066
7.
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
Drugs;
67(17): 2656, 2007.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18034598
8.
Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Haematologica;
88(9): 1074-6, 2003 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12969819
9.
Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Cancer;
109(10): 2068-76, 2007 May 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17429836
10.
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood;
110(2): 727-34, 2007 Jul 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17405907
11.
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Blood;
109(11): 4686-92, 2007 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17317858
12.
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood;
108(5): 1469-77, 2006 Sep 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16638934
13.
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hematology Am Soc Hematol Educ Program;
: 118-22, 2005.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16304368
14.
Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia.
Ann Hematol;
84(11): 734-41, 2005 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15951986
15.
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Cancer;
104(12): 2717-25, 2005 Dec 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16294345
16.
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood;
106(2): 458-63, 2005 Jul 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15817679
17.
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Blood;
102(2): 659-61, 2003 Jul 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12663457
18.
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Blood;
101(1): 85-90, 2003 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12393581
19.
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Blood;
103(4): 1495-8, 2004 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14576058